- Home
- QLGN vs HSDT Comparison
QLGN vs HSDT Comparison
Compare QLGN & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- HSDT
- Stock Information
- Founded
- QLGN 1996
- HSDT N/A
- Country
- QLGN United States
- HSDT United States
- Employees
- QLGN N/A
- HSDT N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- QLGN Health Care
- HSDT Health Care
- Exchange
- QLGN Nasdaq
- HSDT Nasdaq
- Market Cap
- QLGN 2.8M
- HSDT 2.5M
- IPO Year
- QLGN N/A
- HSDT N/A
- Fundamental
- Price
- QLGN $3.75
- HSDT $1.09
- Analyst Decision
- QLGN
- HSDT Hold
- Analyst Count
- QLGN 0
- HSDT 1
- Target Price
- QLGN N/A
- HSDT N/A
- AVG Volume (30 Days)
- QLGN 10.5K
- HSDT 2.2M
- Earning Date
- QLGN 07-01-2025
- HSDT 05-01-2025
- Dividend Yield
- QLGN N/A
- HSDT N/A
- EPS Growth
- QLGN N/A
- HSDT N/A
- EPS
- QLGN N/A
- HSDT N/A
- Revenue
- QLGN N/A
- HSDT $434,000.00
- Revenue This Year
- QLGN N/A
- HSDT $0.04
- Revenue Next Year
- QLGN N/A
- HSDT $75.10
- P/E Ratio
- QLGN N/A
- HSDT N/A
- Revenue Growth
- QLGN N/A
- HSDT N/A
- 52 Week Low
- QLGN $2.85
- HSDT $0.80
- 52 Week High
- QLGN $29.44
- HSDT $24.00
- Technical
- Relative Strength Index (RSI)
- QLGN 51.20
- HSDT 21.24
- Support Level
- QLGN $3.65
- HSDT $0.80
- Resistance Level
- QLGN $3.98
- HSDT $4.10
- Average True Range (ATR)
- QLGN 0.14
- HSDT 0.49
- MACD
- QLGN -0.01
- HSDT -0.28
- Stochastic Oscillator
- QLGN 51.32
- HSDT 6.61
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.